Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allow...

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

Shares of Eli Lilly hit resistance at the $955 level. Now they are heading lower. These moves are due to investor psychology.

Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation...

Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing ...

Eli Lilly's Weekly Insulin Efsitora Meets Phase 3 Goals, Offering Improved Blood Sugar Control in Type 2 Diabetes.

Eli Lilly and Company (NYSE:LLY) today announced positive topline results from the QWINT-1 and QWINT-3 phase 3 clinical trials ...

This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for...